These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11839818)

  • 1. Phenotypic complementation establishes requirements for specific POU domain and generic transactivation function of Oct-3/4 in embryonic stem cells.
    Niwa H; Masui S; Chambers I; Smith AG; Miyazaki J
    Mol Cell Biol; 2002 Mar; 22(5):1526-36. PubMed ID: 11839818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain.
    Brehm A; Ohbo K; Schöler H
    Mol Cell Biol; 1997 Jan; 17(1):154-62. PubMed ID: 8972195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of Oct-4 activity by Ewing's sarcoma protein.
    Lee J; Rhee BK; Bae GY; Han YM; Kim J
    Stem Cells; 2005; 23(6):738-51. PubMed ID: 15917470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of Ets-2-induced transactivation of the tau interferon promoter by Oct-4.
    Ezashi T; Ghosh D; Roberts RM
    Mol Cell Biol; 2001 Dec; 21(23):7883-91. PubMed ID: 11689681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of altered-specificity binding Oct-4 suggests an absence of pluripotent cell-specific cofactor usage.
    Smith AE; Ford KG
    Nucleic Acids Res; 2005; 33(18):6011-23. PubMed ID: 16243786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human OCT-4 isoforms differ in their ability to confer self-renewal.
    Lee J; Kim HK; Rho JY; Han YM; Kim J
    J Biol Chem; 2006 Nov; 281(44):33554-65. PubMed ID: 16951404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POU domain factors in neural development.
    Schonemann MD; Ryan AK; Erkman L; McEvilly RJ; Bermingham J; Rosenfeld MG
    Adv Exp Med Biol; 1998; 449():39-53. PubMed ID: 10026784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oct-4: gatekeeper in the beginnings of mammalian development.
    Pesce M; Schöler HR
    Stem Cells; 2001; 19(4):271-8. PubMed ID: 11463946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor interactions with Oct-1 and Brn-1 are physically and functionally distinct.
    González MI; Tovaglieri A; Robins DM
    Mol Cell Endocrinol; 2002 Apr; 190(1-2):39-49. PubMed ID: 11997177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1.
    Vigano MA; Staudt LM
    Nucleic Acids Res; 1996 Jun; 24(11):2112-8. PubMed ID: 8668543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DPPA4 and other genes as putative Sox2:Oct-3/4 target genes using a combination of in silico analysis and transcription-based assays.
    Chakravarthy H; Boer B; Desler M; Mallanna SK; McKeithan TW; Rizzino A
    J Cell Physiol; 2008 Sep; 216(3):651-62. PubMed ID: 18366076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2.
    Nishimoto M; Fukushima A; Okuda A; Muramatsu M
    Mol Cell Biol; 1999 Aug; 19(8):5453-65. PubMed ID: 10409735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells.
    Okumura-Nakanishi S; Saito M; Niwa H; Ishikawa F
    J Biol Chem; 2005 Feb; 280(7):5307-17. PubMed ID: 15557334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox regulation of the embryonic stem cell transcription factor oct-4 by thioredoxin.
    Guo Y; Einhorn L; Kelley M; Hirota K; Yodoi J; Reinbold R; Scholer H; Ramsey H; Hromas R
    Stem Cells; 2004; 22(3):259-64. PubMed ID: 15153603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oct-3/4 maintains the proliferative embryonic stem cell state via specific binding to a variant octamer sequence in the regulatory region of the UTF1 locus.
    Nishimoto M; Miyagi S; Yamagishi T; Sakaguchi T; Niwa H; Muramatsu M; Okuda A
    Mol Cell Biol; 2005 Jun; 25(12):5084-94. PubMed ID: 15923625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Oct-2 glutamine-rich and proline-rich activation domains can synergize with each other or duplicates of themselves to activate transcription.
    Tanaka M; Clouston WM; Herr W
    Mol Cell Biol; 1994 Sep; 14(9):6046-55. PubMed ID: 8065338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All known in vivo functions of the Oct-2 transcription factor require the C-terminal protein domain.
    Corcoran LM; Koentgen F; Dietrich W; Veale M; Humbert PO
    J Immunol; 2004 Mar; 172(5):2962-9. PubMed ID: 14978099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains.
    Abdulkadir SA; Casolaro V; Tai AK; Thanos D; Ono SJ
    J Leukoc Biol; 1998 Nov; 64(5):681-91. PubMed ID: 9823775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the transactivation domain of the Oct-6 POU transcription factor.
    Meijer D; Graus A; Grosveld G
    Nucleic Acids Res; 1992 May; 20(9):2241-7. PubMed ID: 1594443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1.
    Murphy S
    Nucleic Acids Res; 1997 Jun; 25(11):2068-76. PubMed ID: 9153304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.